Hosta

by | Mar 16, 2018 | Hosta

How Can We Help?
You are here:
< Back

Pavinetant (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS).[1][2][3] It was also under investigation for the treatment of schizophrenia,[2] but development was discontinued for this indication due to lack of effectiveness.[1][4] In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.[1][3]

See also

References

  1. ^ a b c "Pavinetant - Millendo Therapeutics - AdisInsight".
  2. ^ a b Malherbe P, Ballard TM, Ratni H (2011). "Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010)". Expert Opin Ther Pat. 21 (5): 637–55. doi:10.1517/13543776.2011.568482. PMID 21417773. S2CID 207473995.
  3. ^ a b Sassarini J, Anderson RA (2017). "New pathways in the treatment for menopausal hot flushes". Lancet. 389 (10081): 1775–1777. doi:10.1016/S0140-6736(17)30886-3. hdl:20.500.11820/f7c16947-678f-40f6-ac53-73343a9d44e7. PMID 28385351.
  4. ^ Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ (2014). "The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study". J Clin Psychopharmacol. 34 (2): 199–204. doi:10.1097/JCP.0000000000000071. PMID 24525659. S2CID 33936765.

External links



Categories
Table of Contents